Sinopharm offers to take China-TCM private in nearly $3 bln deal
Feb 21 (Reuters) - China National Pharmaceutical Group
has revived a take-private bid for China Traditional Chinese
Medicine Holdings 0570.HK , valuing the Hong-Kong listed
drugmaker at HK$23.16 billion ($2.96 billion).
China National Pharmaceutical, also known as Sinopharm, is
the parent of the drugmaker and had in 2021 decided against a
possible privatisation of China TCM.
($1 = 7.8215 Hong Kong dollars)
(Reporting by Rishav Chatterjee in Bengalurul; Editing by Arun
Koyyur)
((Rishav.Chatterjee@thomsonreuters.com;))
Recent news on China Traditional Chinese Medicine Holdings Co
See all newsBrief: China Traditional Chinese Medicine Says Shaoyao Gancao Tang And Taohe Chengqi Tang Granules Approved For Marketing
Brief: China Traditional Chinese Medicine Loss For Year Rmb458.1 Million
Brief: China Traditional Chinese Medicine Sees Net Loss For Year
Tennis-Fritz fires on final day as Team World land third Laver Cup title (updated)
Brief: China Traditional Chinese Medicine Says Unit Entered Alcohol Extraction Workshop Construction Project, Others